Search PubMed⌕ Search

Biomedical subjects

C Sauter

Publications and source records attributed to C Sauter.

At least 109 records · Page 6Linked to original sources
PubMed1980

[Acute myeloblastic leukemia in adults: a cure in sight?].

The author inquires what the chances are in 1980 of curing acute myeloblastic leukemia (AML) in adults. Efforts toward curative treatment are chiefly concentrated in three places: the basic science laboratories, the clinical laboratories, and the bedside. It remains an open question from which quarter the decisive findings for the prevention or cure of AML will come. For the time being, only clinical trials offer substantial help to AML sufferers. A small number of patients achieve many years of remission and are perhaps even cured, but it is impossible to predict what patients can expect longterm remissions. Painstaking investigation of this group of patients may provide the clue to curative treatment for AML as early as the present decade.

Adult↗
PubMed1980

[Burkitt's lymphoma in a Swiss patient].

In summer 1978, Burkitt lymphoma was diagnosed in a 23 year old Swiss male. A brief report on this patient appears justified for the following reasons: (1) Burkitt lymphoma is very rarely diagnosed in Switzerland. (2) The tumor cells of this patient could be established as a cell line. They have now been subpassaged in vitro for over 9 months. (3) In contrast to the majority of non-African Burkitt lymphomas, these tumor cells produce small amounts of Epstein-Barr virus.

Adult↗
PubMed1980

[Acute leukemia after kidney allotransplantation (author's transl)].

Four cases of acute myelogenous leukemia and six cases of chronic myelogenous leukemia after treatment with azathioprine and prednisone for renal allotransplantation have been described in the literature. We report another two cases of acute leukemia 10 and 5 years after successful renal allotransplantation. Patient 1, a 29-year-old farmer, exhibited the signs of acute lymphatic leukemia resistent to treatment with cytostatic agens. Death was due to pneumonia. Patient 2, a 47-year-old salesman, developed pancytopenia together with splenomegaly. After splenectomy an atypical subacute myeloid leukemia became apparent which was not treated due to withdrawal of the patient. He died 2 months after diagnosis. Both patients received long-term immunosuppressive therapy with azathiopine and prednisone until the leukemia was diagnosed. A relationship between long-term immunosuppression and the occurrence of leukemia is postulated.

Adult↗
PubMed1979

[A possible new prognostic criterium for acute myelocytic leukemia: speed of the titer increase of antiviral antibodies after virus oncolysate injections].

In a study conducted by the Swiss Group for Clinical Cancer Research, 28 patients with acute myelogenous leukemia in complete remission were treated by chemotherapy and viral oncolysate (i.e. formalin treated fowl plague virus infected allogenous leukemia cells). Patients with a slow rise and low maximal titers of antiviral antibodies in the sera proved to have longer remissions than those with a prompt and high rise. Several patients showed association of antiviral antibody changes in the serum with the percentage of myeloblasts in the bone marrow. Determination of the antiviral antibody titer slope after repeated immunization by viral oncolysate can therefore be used for prognosis in patients with acute myelogenous leukemia in remission, and may be helpful in detecting inadequately treated patients.

Antibodies, Viral↗
PubMed1979

[Cellular immunity: in vitro leukocyte migration inhibition does not correlate with the tuberculin skin test].

The leukocyte migration inhibition test (LMIT) is said to be an in-vitro correlate of cell mediated immunity in vivo. The authors' series of experiments, however, in which they compared skin tests and LMIT (taking the same tuberculin for both tests), showed wed no correlation between the two tests. The discrepancy between these results and those of other authors may be due to the fact that the authors worked under sterile conditions. It is known that contamination even by minute amounts of endotoxin may alter the results of in-vitro tests of cell mediated immunity. The authors therefore question the value of the LMIT as an in-vitro counterpart of the skin test.

Blood Sedimentation↗
PubMed1979

Action of cytosine arabinoside on human tumor cells isolated from malignant effusions: in vitro phosphorylation and inhibition of DNA synthesis.

Tumor cells were isolated from malignant effusions of three patients with disseminated solid tumors of different origin. Intracellular accumulation of nondiffusible cytosine arabinoside (ara-C) nucleotides was used to measure phosphorylation. Mouse leukemia L 1210 and L 1210/CA, and ara-C-resistant subline, were used as reference cells. Phosphorylation activity was similar in the cells from all three solid tumors and showed a linear increase with drug concentrations of 0.1--100 micograms/ml. In contrast to activity in L 1210 cells, the in vitro activity was not saturable at drug levels up to 100 micrograms/ml. Ara-C inhibited the incorporation of thymidine into DNA 84%--90% in the solid tumor cells at a concentration of 10 micrograms/ml. Higher drug concentrations did not result in further inhibition. In one patient, DNA synthesis of tumor cells isolated before and after intraperitoneal instillation of 1,000 mg ara-C was measured. The in vivo inhibition was found to correspond to the in vitro data. Solid tumor cells isolated from malignant effusion have no greatly reduced capacity for cellular formation of ara-C/nucleotides, but higher drug levels than achieved with conventional therapy are necessary for sufficient ara-C nucleotide synthesis.

Ascites↗
PubMed1978

[Granulocyte substitution in febrile leukemia patients with bone marrow aplasia. 1. Results of a prospective study].

A prospective, randomized study was performed in aplastic, granulocytopenic, infected patients with acute leukemia during induction therapy. 12 patients received antibiotics alone, and 13 received antibiotics plus 1.7-14.7 X 10(10) (MEAN 6.6 X 10(10) granulocytes by 1-5 (mean 2.7) daily transfusions. In 10 of 12 controls the infection resolved and remission was achieved with granulocyte counts greater than 500/mm3 15 +/- 9 days after randomization. In the transfused patients, infection was brought under control in 10 out of 13 and remission was achieved with granulocyte counts greater than 500/mm3 25+/- 11 days after randomization. Only one death due to infection was observed (6 days after randomization, control).

Anemia, Aplastic↗
PubMed1978

[Isolation of human tumor cells: conditions for in vitro diagnostic and therapeutic studies (proceedings)].

With a view to the possible use of human tumor cells for diagnostic and therapeutic tests (e.g. determination of hormone receptors, sensitivity to cytotoxic drugs, cytotoxicity tests), an attempt has been made to isolate and cultivate pure human tumor cell populations. 49 malignant effusions from 42 patients formed the starting material. The tumor cell isolation was carried out in three steps: 1. elimination of erythrocytes by density-gradient centrifugation or osmotic lysis with triple distilled water; 2. concentration of tumor cells by lg-sedimentation; 3. elimination of adherent cells by short term cultivation in plastic tissue culture flasks. This procedure yielded 95-98% tumor cells. From these suspensions of purified tumor cells, primary cultures were successfully established by supplementing the tissue culture media with autologous effusion fluid.

Cells, Cultured↗
PubMed1977

[Antiviral activity in the serum of patients with acute myelocytic leukemia: prognostic significance. Preliminary report].

In view of suggestions that acute myeloblastic leukemia (AML) may be of viral etiology, sera of 31 patients suffering from AML were investigated for antiviral activity. Fowl plague virus (FPV), vesicular stomatitis virus (VSV), BT 20 mammary carcinoma cells and chicken embryo fibroblasts (CEF) were used as assay systems. In the FPV-BT20 system, 19 of 20 patients whose blood sample was taken when they were in complete remission showed antiviral activity in their sera. These patients stayed in complete remission for at least three months after the blood sample was taken. In the sera of 11 patients no antiviral activity could be found with the FPV-BT20 assay system. 3 of the 11 were in relapse, 5 had a relapse within 3 months and 3 stayed in remission more than 3 months after the blood sample was taken. In the FPV-CEF and in the VSV-BT20 system antiviral activity was also found. The activity in the FPV-CEF system corresponded well with the FPV-BT20 assay and the disease status, whereas the activity detected by the VSV-BT20 system did not. The nature of the antiviral activities in the sera of AML patients against FPV and VSV is not yet clear. Interferon and specific antiviral antibodies can probably be ruled out. The antiviral activity against FPV appears to be a biological index of the activity of the disease and might eventually be used to determine intensity and length of treatment.

Animals↗
PubMed1977

[Therapeutic results and prognostic factors in acute lymphatic leukemia in the adult].

Induction chemotherapy consisting of vincristine, prednisone and L-asparaginase was given to 22 adult patients with acute lymphatic leukemia. Manintenance treatment consisted of methotrexate, 6-mercaptopurine, prednisone and vincristine. Of the 22 patients treated, 14 had a complete remission. The median remission duration was 14 months and the median survival 20 months. 8 further patients were included in an attempt to determine the significance of prognostic factors, but none of the parameters studied influence the course of disease with statistical significance. In general, younger patients and those with lower leukocyte counts at the time of diagnosis seemed to fare better.

Adult↗
PubMed1977

[Not Available].

Explore the source record for details and available documents.

France↗
PubMed1976

[The treatment of acute myelocytic leukemia during the first recurrence by means of a new cytostatic combination].

Fifteen patients with acute myeloic leukemia in the first relapse following initial therapy were treated with a combination of adriamycin, vincristine, 6-thioguanine and the new podophyllotoxin derivative VP 16-213. Complete remission was obtained in 3 cases and partial remission in 3 further patients. The combination was generally well tolerated. These preliminary results are compared with those available in the relatively meagre literature. The study is being continued.

Cytarabine↗
PubMed1975

[The therapy of acute myelogenous leukemia].

In the last few years tremendous progress has been made in the treatment of acute myelogenous leukemia: remissions have been observed more frequently and they last longer. Present-day therapy is described. It has become so complex that induction therapy must be carried out by oncologic departments. Maintenance treatment can however be conducted by the family physician, acting in close cooperation with the oncology unit.

Cyclophosphamide↗